MetaVia Doses First Patient in Phase 1 Part 3 Trial of Obesity Candidate DA-1726

On April 10, 2026, MetaVia Inc. announced the dosing of the first patient in Part 3 of its Phase 1 clinical trial for DA-1726, a novel dual oxyntomodulin (OXM) analog targeting GLP-1 and glucagon receptors for the treatment of obesity. This portion of the study consists of two 16-week titration cohorts (Part 3A and Part 3B) designed to evaluate one-step and two-step dose-escalation strategies to reach target doses of 48 mg and 64 mg, respectively. The trial aims to enroll approximately 40 obese, otherwise healthy adults to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of these higher-dose regimens. Previous data from the Phase 1 program showed approximately 9% weight loss at the 48 mg dose with a favorable safety profile. MetaVia believes the dual-agonist approach may offer superior weight loss and energy expenditure compared to selective GLP-1 agonists. The company expects to report data from these higher-dose cohorts in the fourth quarter of 2026.